1Gillissen A, Bartling A, Scboen S, et al. Antioxidant Function, of Ambroxol in Mononuclcar and Poly Morphonuclear Cells In Vitro[J]. Lung, 1997,175(3) :235.
2Watter R R, Schamalisch G, Boehme B, et al. Randomized Double Blind Trial of Ambrotol for the Treatment of Respiratory Distress Syndrom[J]. Eur J Pediaty, 1992, 151 (5) : 357- 363.
3Schmalisch G, Waner R R, Bohme B. Changes in Pulmonary Function in Preterm Infant Recovering from RDS Following Early Treatment with Ambroxol:Results of a Randomized Trial[J]. Pediatr Pulmonol, 1999,27(2) : 104-112.
5Luerti M, Parazzini F, Agarossi A, et al. Risk factors for respiratory distress syndrome in newborn [ J ]. Acto Obstet Gymecol Sconcl, 1993,72:359 - 4.
6Yang B, Yao DF, Ohuchi M, et al. Ambroxol suppresses influenza- virus proliferation in the mouse airway by increasing antiviral factor levels[ J]. Eur Respir,2002,19 ( 5 ) :952 - 8.
7Ottonello L, Arduino N, Bertolotto M, et al. In vitro inhibition of human neutrophil histotoxicity by ambroxol: evidence for a multistep mechanism[J]. British Journal of Pharmacology,2003,140(4) :736 -42.
8Gillissen A, Nowak D. Characterization of N - acetylcysteine and ambroxol in anti - oxidant therapy [ J ]. Respir Med, 1998,92 (4) :609 -23.
9Laoag - Fernandez JB, Fernandez AM, Marao T. Antenatal use of ambroxol in the prevention of infant respiratory distress syndrome [ J ]. J Obstel Gynaecol Res, 2000,26 (4) : 307 - 12.
10SWEET D G, CARNIELLI V, GREISEN G, et al. European consensus guidelines on the management of neonatal respiratory distress syndrome in preterm infants-2010 update[J]. Neonatology,2010,97(4):402- 417.
